Paper Details

  1. Home
  2. Paper Details

[Immunomodulator drugs for the treatment of multiple myeloma].

Author: Caballero GarcíaAlberto, Córdova MartínezAlfredo, Fernández-LázaroCésar Ignacio, Fernández-LázaroDiego

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Second-generation immunomodulatory (IMiDs) compounds, lenalidomide and pomalidomide, are highly effective and well-tolerated treatment options for patients with multiple myeloma.
Paper Details　
Original Abstract of the Article :
Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immuno...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.4067/s0034-98872018001201444

データ提供：米国国立医学図書館（NLM）

Immunomodulators in Multiple Myeloma: A New Era of Treatment Options

Multiple myeloma, a complex hematological malignancy, has long been a formidable foe for oncologists. This research explores the evolution of immunomodulatory drugs (IMiDs) in the treatment of multiple myeloma. The study delves into the development of second-generation IMiDs, lenalidomide and pomalidomide, examining their mechanisms of action, efficacy, and safety profiles, offering a comprehensive overview of these promising therapeutic agents.

The Rise of Immunomodulators: A New Frontier in Multiple Myeloma Treatment

The research highlights the significant advancements in the treatment of multiple myeloma with the emergence of second-generation IMiDs. Lenalidomide and pomalidomide demonstrate remarkable efficacy in reducing tumor burden and prolonging survival. These drugs offer a potent weapon against multiple myeloma, often used in combination with dexamethasone, a corticosteroid, to enhance their therapeutic effects.

Living with Multiple Myeloma: Hope on the Horizon

This research offers a beacon of hope for individuals diagnosed with multiple myeloma. The development of second-generation IMiDs has revolutionized the treatment landscape, offering improved efficacy and tolerability compared to earlier generations of drugs. This progress underscores the importance of ongoing research in the pursuit of effective treatments for this challenging disease.

Dr. Camel's Conclusion

This research is a testament to the progress made in the fight against multiple myeloma. The emergence of second-generation IMiDs offers a new era of hope for patients, promising more effective and less toxic treatments. This study highlights the relentless pursuit of innovative therapies in the quest to conquer this complex disease.

Date :
  1. Date Completed 2019-03-13
  2. Date Revised 2019-03-13
Further Info :

Pubmed ID

30848748

DOI: Digital Object Identifier

10.4067/s0034-98872018001201444

Related Literature

Article Analysis
・Side Effects of pomalidomide
SNS
PICO Info
in preparation
Languages

Spanish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.